In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...

A man spent 18 years injecting himself with venom, almost dying more than once – and now his blood is behind a new snakebite treatment.

A recent study marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells. As a proof-of-concept, the ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

Genialis, the RNA biomarker company, today announced two new studies demonstrating how predictive algorithms can drive better outcomes for patients, providers, and drug developers. In poster ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved ...

The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC”) linker ... financial or operating performance. For ...